Efavirenz as a Substitute for Protease Inhibitors in HIV-1–Infected Patients With Undetectable Plasma Viral Load on HAART: A Median Follow-Up of 64 Weeks
- 1 August 2001
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 27 (5) , 459-462
- https://doi.org/10.1097/00042560-200108150-00006
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment databaseAIDS, 2001
- Antiretroviral Therapy in AdultsJAMA, 2000
- A Randomized Trial of Three Maintenance Regimens Given after Three Months of Induction Therapy with Zidovudine, Lamivudine, and Indinavir in Previously Untreated HIV-1–Infected PatientsNew England Journal of Medicine, 1998
- Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug TherapyNew England Journal of Medicine, 1998
- HIV-Protease InhibitorsNew England Journal of Medicine, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral TherapyScience, 1997
- Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patientsAIDS, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995